Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Receives $76.59 Average Target Price from Analysts

Share on StockTwits

Shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) have been assigned an average recommendation of “Buy” from the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $73.62.

TRHC has been the subject of a number of recent research reports. Zacks Investment Research cut Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Saturday. ValuEngine raised Tabula Rasa HealthCare from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. BidaskClub cut Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Friday, October 11th. Piper Jaffray Companies dropped their target price on Tabula Rasa HealthCare from $78.00 to $66.00 and set an “overweight” rating for the company in a report on Friday. Finally, Stifel Nicolaus raised Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and increased their target price for the stock from $50.00 to $75.00 in a report on Friday, August 30th.

Shares of TRHC traded down $4.11 during trading hours on Thursday, hitting $45.94. 1,365,800 shares of the company were exchanged, compared to its average volume of 352,947. Tabula Rasa HealthCare has a 52 week low of $40.86 and a 52 week high of $78.20. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.90 and a current ratio of 1.97. The firm’s 50 day moving average is $52.19 and its 200-day moving average is $52.87. The company has a market cap of $1.12 billion, a PE ratio of 135.12 and a beta of 1.62.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Thursday, August 8th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.29. Tabula Rasa HealthCare had a positive return on equity of 3.63% and a negative net margin of 7.09%. The business had revenue of $76.26 million during the quarter, compared to analysts’ expectations of $70.40 million. During the same period in the prior year, the firm posted $0.20 EPS. Tabula Rasa HealthCare’s quarterly revenue was up 56.9% compared to the same quarter last year. As a group, equities analysts forecast that Tabula Rasa HealthCare will post -0.15 earnings per share for the current fiscal year.

In related news, President Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $56.05, for a total transaction of $448,400.00. Also, Director Gordon Tunstall sold 10,000 shares of the firm’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $65.01, for a total value of $650,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 65,000 shares of company stock valued at $3,692,490 over the last ninety days. Insiders own 11.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Cutler Group LP boosted its position in Tabula Rasa HealthCare by 126.9% in the 3rd quarter. Cutler Group LP now owns 700 shares of the company’s stock valued at $38,000 after buying an additional 3,300 shares during the last quarter. Aperio Group LLC bought a new position in Tabula Rasa HealthCare in the 2nd quarter valued at $39,000. Nisa Investment Advisors LLC bought a new position in Tabula Rasa HealthCare in the 3rd quarter valued at $47,000. Oppenheimer Asset Management Inc. bought a new position in Tabula Rasa HealthCare in the 3rd quarter valued at $49,000. Finally, First Mercantile Trust Co. boosted its position in Tabula Rasa HealthCare by 20.3% in the 2nd quarter. First Mercantile Trust Co. now owns 1,197 shares of the company’s stock valued at $60,000 after buying an additional 202 shares during the last quarter. 99.00% of the stock is owned by hedge funds and other institutional investors.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

See Also: Special Dividends

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.